KURA — Kura Oncology, Inc. stock price, charts and financials

Latest market price

9.60

+0.02+0.26%

Overview Short InterestFilings

KURAQT66Kura Oncology, Inc.·NASDAQ

Overview Short InterestFilings

9.60+0.26%

Loading chart...

Signal & projected range

QT Score upgradeHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.40%$15.47 MESO+4.89%$16.72 ZBIO-1.46%$31.96 GHRS-1.65%$29.77 TSHA-1.45%$6.46 STOK-1.65%$32.17 ABCL+36.44%$9.46 VRDN-3.25%$22.82

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.35	Insider Own	11.01%	Shs Outstand	88.77M	Perf Week	6.22%

Market Cap	849.57M	Forward P/E	-	EPS next Y	-2.61	Insider Trans	-1.02%	Shs Float	86.00M	Perf Month	-20.78%

Enterprise Value	834.76M	PEG	0.07	EPS next Q	-	Inst Own	-	Short Float	15.97%	Perf Quarter	2.68%

Income	-295.14M	P/S	11.86	EPS this Y	-4.14%	Inst Trans	-	Short Ratio	7.72	Perf Half Y	29.32%

Sales	71.64M	P/B	7.86	EPS next Y	25.18%	ROA	-45.14%	Short Interest	13.73M	Perf YTD	-7.89%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-141.95%	52W High	12.52 -23.38%	Perf Year	58.71%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-57.53%	52W Low	5.46 75.60%	Perf 3Y	-6.82%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	94.66%	Volatility	4.10% 4.92%	Perf 5Y	-49.47%

Dividend TTM	-	EV/Sales	11.65	EPS Y/Y TTM	-65.84%	Oper. Margin	-443.54%	ATR (14)	0.50	Perf 10Y	141.67%

Dividend Ex-Date	-	Quick Ratio	6.14	Sales Y/Y TTM	31.48%	Profit Margin	-411.19%	RSI (14)	44.46	Recom	2.12

Dividend Gr. 3/5Y	-	Current Ratio	6.15	EPS Q/Q	-25.76%	SMA20	-5.06%	Beta	0.38	Target Price	22.57

Payout	0.00%	Debt/Eq	0.23	Sales Q/Q	28.57%	SMA50	-4.96%	Rel Volume	0.43	Prev Close	9.57

Employees	260	LT Debt/Eq	0.11	Earnings	Aug 12	SMA200	-0.60%	Avg Volume	1.74M	Price	9.60

IPO Date	Sep 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.54% -29.67%	Net Debt/EBITDA	0.05	Volume	749,056	Change	0.26%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-15-26	Reiterated	Bernstein		$24
Jun-04-26	Reiterated	Wells Fargo		$24
Jun-04-26	Reiterated	CLSA		$24
May-28-26	Reiterated	Jefferies	Buy	$24
May-28-26	Reiterated	Oppenheimer	Outperform	$24
Apr-14-26	Initiated	Lake Street	Buy	$23
Mar-13-26	Reiterated	UBS	Buy	$14 → $15
Jan-13-26	Reiterated	Leerink Partners	Outperform	$20
Nov-24-25	Reiterated	Barclays	Overweight	$28
Nov-14-25	Reiterated	H.C. Wainwright	Buy	$32

Latest News

Today

Today08:32AM

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activityglobenewswire.com

Aug-07-26

Aug-07-2607:30AM

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Aug-05-26

Aug-05-2607:30AM

Kura Oncology to Report Second Quarter Financial Resultsglobenewswire.com

Jul-29-26

Jul-29-2607:06PM

Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma - SlideshowSeekingAlpha

Jul-27-26

Jul-27-2603:38PM

Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma TranscriptSeekingAlpha

12:02PM

Kura Oncology Reports 50% Response Rate in RCC Combination Studymarketbeat.com

06:32AM

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026globenewswire.com

Jul-14-26

Jul-14-2604:48PM

A Fresh Look At Syndax PharmaceuticalsSeekingAlpha

07:02AM

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026globenewswire.com

Jul-08-26

Jul-08-2607:23AM

Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Winseekingalpha.com

Jul-03-26

Jul-03-2607:30AM

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-02-26

Jul-02-2602:08AM

Kura Oncology Reports Q1 2026 Results: Full Earnings Call TranscriptBenzinga

Jun-15-26

Jun-15-2609:59AM

Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price TargetBenzinga

Jun-13-26

Jun-13-2601:30AM

Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowSeekingAlpha

Jun-12-26

Jun-12-2607:02PM

Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML TranscriptSeekingAlpha

Company

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	71	67	54	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	4	0	0	—	—	—	—	—	—
Gross Profit	68	67	54	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	128	120	77	—	—	—	—	—	—
Research and Development	260	251	170	—	—	—	—	—	—
Other Operating Expense	-2	0	0	—	—	—	—	—	—
Operating Income	-318	-304	-193	—	—	—	—	—	—
Interest Expense	0	2	2	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	25	27	23	—	—	—	—	—	—
Net Income Before Taxes	-294	-278	-172	—	—	—	—	—	—
Income Taxes	0	0	2	—	—	—	—	—	—
Consolidated Net Income	-294	-279	-174	—	—	—	—	—	—
Net Income From Continuing Operations	-294	-279	-174	—	—	—	—	—	—
Net Income	-294	-279	-174	—	—	—	—	—	—
EPS (Recurring)	-3.35	-3.18	-2.02	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.35	-3.18	-2.02	—	—	—	—	—	—
EPS (Diluted)	-3.35	-3.18	-2.02	—	—	—	—	—	—
EBITDA	-293	-276	-169	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	12.03	13.65	13.87	—	—	—	—	—	—
Gross Margin	95.77	100.00	100.00	—	—	—	—	—	—
Operating Margin	-447.89	-453.73	-357.41	—	—	—	—	—	—
Net Margin	-414.08	-416.42	-322.22	—	—	—	—	—	—
Shares Outstanding	89	88	86	—	—	—	—	—	—
Market Capitalization	854	914	749	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leoni Mollie	Chief Medical Officer	Jun 18 '26	Sale	9.82	84,929	834,283	182,345	Jun 22
Powl Brian T.	Chief Commercial Officer	May 21 '26	Sale	11.00	10,000	110,000	173,614	May 22
FORD KATHLEEN	Chief Operating Officer	May 19 '26	Sale	9.08	2,257	20,483	153,560	May 20
Powl Brian T.	Chief Commercial Officer	May 19 '26	Sale	9.21	339	3,122	183,614	May 20
Bair Teresa Brophy	Chief Legal Officer	May 18 '26	Sale	9.38	2,256	21,160	226,931	May 20
WILSON TROY EDWARD	President and CEO	Mar 23 '26	Option Exercise	6.15	12,206	75,066	435,456	Mar 25
Malley Thomas	Director	Mar 18 '26	Option Exercise	3.12	20,000	62,400	10,000	Mar 20
Bair Teresa Brophy	Chief Legal Officer	Jan 27 '26	Sale	8.46	11,208	94,828	226,931	Jan 27
Powl Brian T.	Chief Commercial Officer	Jan 27 '26	Sale	8.46	6,414	54,266	183,275	Jan 27
FORD KATHLEEN	Chief Operating Officer	Jan 27 '26	Sale	8.46	1,813	15,339	153,560	Jan 27
Leoni Mollie	Chief Medical Officer	Jan 27 '26	Sale	8.46	8,180	69,209	267,274	Jan 27
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 27 '26	Sale	8.46	7,142	60,427	145,167	Jan 27
Burrows Francis	Chief Scientific Officer	Jan 27 '26	Sale	8.46	1,311	11,092	32,424	Jan 27
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Option Exercise	4.80	35,000	168,000	57,461	Dec 19
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Sale	9.78	23,726	231,931	33,735	Dec 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.